<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162420</url>
  </required_header>
  <id_info>
    <org_study_id>2013OC127</org_study_id>
    <secondary_id>MT2013-34C</secondary_id>
    <nct_id>NCT02162420</nct_id>
  </id_info>
  <brief_title>Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia</brief_title>
  <official_title>Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fludarabine-based preparative regimen followed by an allogeneic hematopoietic stem cell&#xD;
      transplant using related or unrelated donor in persons 0-70 years of age diagnosed with&#xD;
      dyskeratosis congenita or severe aplastic anemia who have bone marrow failure characterized&#xD;
      by a requirement for red blood cell and platelet transfusions. Three different preparative&#xD;
      regimens are included based on disease and donor type.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of neutrophil engraftment</measure>
    <time_frame>Day 42</time_frame>
    <description>Incidence of neutrophil engraftment by day 42.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of platelet engraftment</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of platelet engraftment at 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of regimen related mortality</measure>
    <time_frame>Day 100</time_frame>
    <description>Incidence of regimen related mortality by day 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute graft-versus-host disease</measure>
    <time_frame>Day 100</time_frame>
    <description>Incidence of acute graft-versus-host disease by day 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic graft-versus-host disease</measure>
    <time_frame>6 Months</time_frame>
    <description>Incidence of chronic graft-versus-host disease by 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic graft-versus-host disease</measure>
    <time_frame>1 Year</time_frame>
    <description>Incidence of chronic graft-versus-host disease by 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of secondary malignancies</measure>
    <time_frame>1 Year</time_frame>
    <description>Incidence of secondary malingancies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dyskeratosis Congenita</condition>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Treatment Plan for Dyskeratosis Congenita</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine based preparative regimen, including alemtuzumab, cyclophosphamide, fludarabine, and total body irradiation, followed by stem cell transplant for the treatment of dyskeratosis congenita.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment for Severe Aplastic Anemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine based preparative regimen which includes: cyclophosphamide, fludarabine, rabbit ATG and total body irradiation. Followed by stem cell transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.</description>
    <arm_group_label>Treatment Plan for Dyskeratosis Congenita</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.</description>
    <arm_group_label>Treatment Plan for Dyskeratosis Congenita</arm_group_label>
    <arm_group_label>Treatment for Severe Aplastic Anemia</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.</description>
    <arm_group_label>Treatment Plan for Dyskeratosis Congenita</arm_group_label>
    <arm_group_label>Treatment for Severe Aplastic Anemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>TBI 200 cGy as a single fraction on day -1 from transplant.</description>
    <arm_group_label>Treatment for Severe Aplastic Anemia</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stem Cell Transplant</intervention_name>
    <description>Stem cell transplant on day 0.</description>
    <arm_group_label>Treatment Plan for Dyskeratosis Congenita</arm_group_label>
    <arm_group_label>Treatment for Severe Aplastic Anemia</arm_group_label>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-thymocyte globulin</intervention_name>
    <description>ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.</description>
    <arm_group_label>Treatment for Severe Aplastic Anemia</arm_group_label>
    <other_name>Rabbit ATG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 0 - 70 years&#xD;
&#xD;
          -  Acceptable hematopoeitic stem cell donor&#xD;
&#xD;
          -  Dyskeratosis Congenita (DC) with evidence of BM failure defined as:&#xD;
&#xD;
               -  requirement for red blood cell and/or platelet transfusions or&#xD;
&#xD;
               -  requirement for G-CSF or GM-CSF or erythropoietin or&#xD;
&#xD;
               -  refractory cytopenias having one of the following three&#xD;
&#xD;
                    -  platelets &lt;50,000/uL or transfusion dependent&#xD;
&#xD;
                    -  absolute neutrophil count &lt;500/uL without hematopoietic growth factor&#xD;
                       support&#xD;
&#xD;
                    -  hemoglobin &lt;9g/uL or transfusion dependent&#xD;
&#xD;
          -  Diagnosis of DC with a triad of mucocutaneous features:&#xD;
&#xD;
               -  oral leukoplakia&#xD;
&#xD;
               -  nail dystrophy&#xD;
&#xD;
               -  abnormal reticular skin hyperpigmentation, or&#xD;
&#xD;
          -  Diagnosis of DC with one of the following:&#xD;
&#xD;
               -  short telomeres (under a research study)&#xD;
&#xD;
               -  mutation in telomerase holoenzyme (DKC1, TERT, TERC, NOP10, NHP2, TCAB1)&#xD;
&#xD;
               -  mutation in shelterin complex (TINF2)&#xD;
&#xD;
               -  mutation in telomere-capping complex (CTC1)&#xD;
&#xD;
          -  Severe Aplastic Anemia (SAA) primary transplant with evidence of BM failure:&#xD;
&#xD;
               -  Refractory cytopenia defined by bone marrow cellularity &lt;50% (with &lt; 30% residual&#xD;
                  hematopoietic cells)&#xD;
&#xD;
          -  Diagnosis of SAA with refractory cytopenias having one of the following three:&#xD;
&#xD;
               -  platelets &lt;20,000/uL or transfusion dependent&#xD;
&#xD;
               -  absolute neutrophil count &lt;500/uL without hematopoietic growth factor support&#xD;
&#xD;
               -  absolute reticulocyte count &lt;20,000/uL&#xD;
&#xD;
          -  Severe Aplastic Anemia (SAA) requiring a 2nd transplant&#xD;
&#xD;
               -  Graft failure as defined by blood/marrow chimerism of &lt; 5%&#xD;
&#xD;
          -  Early myelodysplastic features&#xD;
&#xD;
          -  With or without clonal cytogenetic abnormalities&#xD;
&#xD;
          -  Adequate organ function defined as:&#xD;
&#xD;
               -  cardiac: left ventricular ejection fraction ≥ 35% with no evidence of&#xD;
                  decompensated heart failure&#xD;
&#xD;
               -  pulmonary: DLCO ≥30% predicted, no supplemental oxygen requirement&#xD;
&#xD;
               -  renal: Glomerular filtration rate (GFR) ≥30% predicted&#xD;
&#xD;
          -  Voluntary written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on&#xD;
             biopsy&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Prior radiation therapy (applies to SAA patients only)&#xD;
&#xD;
          -  Diagnosis of Fanconi anemia based on DEB&#xD;
&#xD;
          -  Diagnosis of dyskeratosis congenita with advanced MDS or acute myeloid leukemia with&#xD;
             &gt;30% blasts&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jakub Tolar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy Krepski</last_name>
    <phone>612-273-2800</phone>
    <email>tkrepsk1@fairview.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Minnesota Medical Center, Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Krepski</last_name>
      <phone>612-273-2800</phone>
      <email>tkrepsk1@fairview.org</email>
    </contact>
    <investigator>
      <last_name>Jakub Tolar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2014</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>severe aplastic anemia</keyword>
  <keyword>Hematopoietic Stem Cell Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Dyskeratosis Congenita</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

